Inclusion Criteria:  patients who are clinically diagnosed as stable CD; the diagnosis of CD has evidence of clinical manifestations and endoscopy, and was confirmed by histopathological report, referring to the consensus opinion on the diagnosis and treatment of inflammatory bowel disease in 2018. CDAI (Crohn's disease activity index)<150 points is regarded as clinical remission. Have reading ability, can access the Internet, use mobile phone WeChat and use application (APP) software with the assistance of oneself or family members;  Exclusion Criteria:  Active patients (referring to CDAI greater than 150); CD patients who currently need or expect surgical intervention during the study period. CD patients with symptoms or signs of perforation such as abdominal abscess, intestinal fistula, etc. Patients with complete intestinal obstruction or fibrous stenosis with pre-stenosis dilation that require surgery to relieve the obstruction. CD patients with colorectal tumors. Those who have EN contraindications (active gastrointestinal bleeding, severe esophageal and gastric varices, intestinal obstruction, abdominal cavity syndrome, etc.). Pregnancy and breastfeeding patients. Severe hemodynamics, unstable vital signs, or the presence of rapid progression or end-stage disease, are expected to die during the course of the study. Patients diagnosed with short bowel syndrome or with ileostomy or colostomy. Patients with severe liver and kidney dysfunction, active infection, or other reasons (such as previous infliximab anaphylactic shock) cannot tolerate the treatment drugs used in this study. The patient is allergic to known ingredients of enteral nutrition or has no previous EEN for 12 weeks.